NCT04528680 2026-04-13
SC9/ABX
Northwestern University
Phase 1/2 Active not recruiting
Clinical Trials
14 trialsNCT04209790 2025-11-10
NeoGlio
Geisinger Clinic
Phase 2 Terminated
NCT03426891 2025-10-06
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT06418113 2024-05-16
GLINERA
Hospital San Carlos, Madrid
Phase 1 Recruiting
NCT05718466 2023-07-17
Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Henry Ford Health System
Phase 3 Completed
NCT02046187 2021-06-16
Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma
St. Joseph's Hospital and Medical Center, Phoenix
Phase 1/2 Terminated
NCT01567202 2020-09-09
Study of DC Vaccination Against Glioblastoma
Huashan Hospital
Phase 2 Unknown
NCT02431572 2020-04-28
A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy
Massachusetts General Hospital
Phase NA Completed
NCT01478854 2019-06-13
Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Completed
NCT00002824 2019-03-13
Gene Therapy in Treating Patients With Primary Brain Tumors
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT03631823 2018-08-15
Gut Microbiota and Glioblastoma Multiforme Prognosis
Huashan Hospital
Unknown
NCT00238277 2018-06-27
Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00003996 2016-12-07
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00274755 2014-05-20
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
University of California, San Francisco
Phase 2 Completed